6-羟基苯并呋喃-3-羧酸 | 115693-71-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 6-羟基苯并呋喃-3-羧酸
• 英文名称: 6-hydroxybenzoforancarboxylic acid
• 英文别名: 6-Hydroxy-1-benzofuran-3-carboxylic acid
• CAS: 115693-71-5
• 化学式: C₉H₆O₄
• mdl: MFCD15144171
• 分子量: 178.144
• InChiKey: QAOIAZYIBZFHKD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  70.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-羟基苯并呋喃-3-羧酸 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium t-butanolate 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.5h， 生成 4-[[3-(Cyclopropylcarbamoyl)-1-benzofuran-6-yl]oxy]-7-methoxyquinoline-6-carboxamide
  参考文献：
  名称：

  EP3293177

  摘要：

  公开号：
• 作为产物：
  描述：

  (3-甲氧基苯氧基)乙酸乙酯 在 氢溴酸 、 sodium ethanolate 作用下， 以 甲基叔丁基醚 、 水 、 溶剂黄146 为溶剂， 反应 4.0h， 生成 6-羟基苯并呋喃-3-羧酸
  参考文献：
  名称：

  Development of a Robust Protocol for the Synthesis of 6-Hydroxybenzofuran-3-carboxylic Acid

  摘要：

  Benzofuran scaffolds are fundamental moieties found in a variety of biologically active natural products and synthetic drugs. In the course of one of our development programs, we needed to develop a practical and cost-effective manufacturing approach to such a benzofuran scaffold. Here we report a highly robust four-step, one-pot process that provides access to a 6-hydroxybenzofuran-3-carboxylic acid structure. An H-1 NMR monitoring study allowed a better understanding of the overall sequence of events and the nature of the detected intermediates. After six steps, including the optimized tandem process, the desired hydroxylated benzofuran was obtained in 40% yield with a purity above 99%.

  DOI：

  10.1021/acs.oprd.9b00546

文献信息

• FUSED CYCLIC COMPOUNDS
  申请人：Yasuma Tsuneo

  公开号：US20100004312A1

  公开（公告）日：2010-01-07

  The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.

  本发明提供一种化合物，其表示为公式（I）：其中每个符号如描述中所定义，或其盐。该化合物或其盐或其前药具有GPR40受体功能调节作用，并可用作胰岛素分泌剂或用于预防或治疗糖尿病等药物。
• Fused cyclic compounds
  申请人：Yasuma Tsuneo

  公开号：US20100197761A1

  公开（公告）日：2010-08-05

  The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.

  本发明提供一种化合物，其化学式表示为（I）：其中每个符号如描述中所定义，或其盐。该化合物或其盐或其前药具有GPR40受体功能调节作用，并且可用作胰岛素分泌剂或预防或治疗糖尿病等疾病的药物。
• Fused cyclic compounds as GPR40 receptor modulators
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2248812A2

  公开（公告）日：2010-11-10

  The present invention provides a pharmaceutical composition comprising a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof, in combination with a dipeptidyl peptidase IV inhibitor, an insulin preparation, a PPAR function modulator, an α-glucosidase inhibitor, a biguanide, a sulfonylurea, mitiglinide or calcium salt hydrate thereof or nateglinide.

  本发明提供了一种药物组合物，其中包含由式 (I) 代表的化合物： 其中各符号如描述中所定义，或其盐与二肽基肽酶 IV 抑制剂、胰岛素制剂、PPAR 功能调节剂、α-葡萄糖苷酶抑制剂、双胍类、磺酰脲类、米格列奈或其钙盐水合物或纳格列奈联合使用。
• TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
  申请人：GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD

  公开号：EP3293177A1

  公开（公告）日：2018-03-14

  The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same. The tyrosine kinase inhibitor of the present invention has the structures as shown in the following formula (I) or (II):

  本发明涉及一种酪氨酸激酶抑制剂及其药物组合物。本发明的酪氨酸激酶抑制剂具有下式（I）或（II）所示的结构：
• Tyrosine kinase inhibitor and pharmaceutical composition comprising same
  申请人：GUANGDONG RAYNOVENT BIOTECH CO., LTD.

  公开号：US10654808B2

  公开（公告）日：2020-05-19

  The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same. The tyrosine kinase inhibitor of the present invention has the structures as shown in the following formula (I) or (II):

  本发明涉及一种酪氨酸激酶抑制剂及其药物组合物。本发明的酪氨酸激酶抑制剂具有下式（I）或（II）所示的结构：